{"filing":{"accession_number":"0001193125-26-384386","cik":"0001782223","ticker":"PYXS","company_name":"Pyxis Oncology, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-03","primary_document":"pyxs-20260903.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526384386/pyxs-20260903.htm"},"events":[{"id":31797,"run_id":29196,"accession_number":"0001193125-26-384386","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Thomas Civik was appointed as permanent Chief Executive Officer and Chairman of the Board, effective September 4, 2026, transitioning from his interim role since February 2026. The appointment includes compensatory arrangements (stock option grant and sign-on bonus), severance terms, and related governance changes including John Flavin's transition to Lead Independent Director and Dr. Palani's resignation.","company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34788,"accession_number":"0001193125-26-384386","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The principal disclosed action is the appointment of Thomas Civik as permanent Chief Executive Officer and Chairman of the Board, effective September 4, 2026. While the filing also includes compensatory arrangements (stock option grant, sign-on bonus, severance terms) and related governance changes (John Flavin's transition to Lead Independent Director, Dr. Palani's resignation), the core event is Civik's elevation from Interim CEO to permanent CEO. This is material to investors as it represents a significant leadership transition at a clinical-stage biopharmaceutical company approaching key clinical milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:40:40.540622+00:00","company_name":"","ticker":null,"filing_date":""},{"id":34789,"accession_number":"0001193125-26-384386","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing announces the appointment of Thomas Civik as Chief Executive Officer and Chairman of the Board, effective September 4, 2026. Although Civik had served as Interim CEO since February 2026, this disclosure centers on his permanent appointment to the top executive role. The press release emphasizes the Board's confidence in his leadership and his strategic focus as the company approaches key clinical milestones for its lead candidate MICVO.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:40:40.540622+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34788,"accession_number":"0001193125-26-384386","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The principal disclosed action is the appointment of Thomas Civik as permanent Chief Executive Officer and Chairman of the Board, effective September 4, 2026. While the filing also includes compensatory arrangements (stock option grant, sign-on bonus, severance terms) and related governance changes (John Flavin's transition to Lead Independent Director, Dr. Palani's resignation), the core event is Civik's elevation from Interim CEO to permanent CEO. This is material to investors as it represents a significant leadership transition at a clinical-stage biopharmaceutical company approaching key clinical milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:40:40.540622+00:00","company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","filing_date":"2026-09-08"},{"id":34789,"accession_number":"0001193125-26-384386","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing announces the appointment of Thomas Civik as Chief Executive Officer and Chairman of the Board, effective September 4, 2026. Although Civik had served as Interim CEO since February 2026, this disclosure centers on his permanent appointment to the top executive role. The press release emphasizes the Board's confidence in his leadership and his strategic focus as the company approaches key clinical milestones for its lead candidate MICVO.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:40:40.540622+00:00","company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","filing_date":"2026-09-08"}]}